Buforin-2 (5-21), sh-Buforin

General Information


DRACP ID  DRACP03567

Peptide Name   Buforin-2 (5-21), sh-Buforin

Sequence  RAGLQFPVGRVHRLLRK

Sequence Length  17

UniProt ID  P55897 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antibacterial



Structure Information


PDB ID  Not available

Predicted Structure  DRACP03567

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C90H155N33O19

Absent amino acids  CDEIMNSTWY

Common amino acids  R

Mass  228900

Pl  12.98

Basic residues  6

Acidic residues  0

Hydrophobic residues  7

Net charge  6

Boman Index  -4592

Hydrophobicity  -38.82

Aliphatic Index  108.82

Half Life 
  Mammalian: 1.3 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 25891844

Title  Hybrid peptide ATCUN-sh-Buforin: Influence of the ATCUN charge and stereochemistry on antimicrobial activity

Doi Not available

Year  2015

Literature 2

Pubmed ID 28314993

Title  Comparative analysis of internalisation, haemolytic, cytotoxic and antibacterial effect of membrane-active cationic peptides: aspects of experimental setup

Doi Not available

Year  2017

Literature 3

Pubmed ID 24803240

Title  Improved bioactivity of antimicrobial peptides by addition of amino-terminal copper and nickel (ATCUN) binding motifs

Doi Not available

Year  2014

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  7651

DRACP is developed by Dr.Zheng's team.